SCHEMBL6100356

SCHEMBL6100356

COc1cc(CC(=O)Nc2cccc(OCCc3ccccc3)c2)ccc1OCCN

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 4/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
LMNA P02545 2/20 0.56
HTT P42858 2/20 0.56
USP2 O75604 1/20 0.55
MEN1 O00255 2/20 0.52
STAT3 P40763 1/20 0.52
BCHE P06276 2/20 0.51
ACHE P22303 2/20 0.51
RAB9A P51151 1/20 0.51
ALDH1A1 P00352 1/20 0.51
MAPT P10636 1/20 0.51
TSHR P16473 1/20 0.51
MAPK1 P28482 1/20 0.51
NPSR1 Q6W5P4 1/20 0.51
HSD17B10 Q99714 1/20 0.51
SIRT2 Q8IXJ6 1/20 0.48
KDM4E B2RXH2 1/20 0.47
CTSD P07339 2/20 0.47
PDGFRB P09619 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6100933 0.90 SMN1; SMN2 (0.63) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6101654 0.85 SMN1; SMN2 (0.63) KMT2ASMN1; SMN2LMNAHTTUSP2
Hydrochloric Acid SCHEMBL6099402 0.84 SMN1; SMN2 (0.62) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6100605 0.84 SMN1; SMN2 (0.62) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6101129 0.84 SMN1; SMN2 (0.57) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6567066 0.83 LMNA (0.56) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6100336 0.83 SMN1; SMN2 (0.60) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6099523 0.83 SMN1; SMN2 (0.61) KMT2ASMN1; SMN2LMNAHTTUSP2
SCHEMBL6099640 0.82 BCL9 (0.58) KMT2ASMN1; SMN2LMNAHTTUSP2
Hydrochloric Acid SCHEMBL6100925 0.82 SMN1; SMN2 (0.60) KMT2ASMN1; SMN2LMNAHTTUSP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7084176-B2 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2006-08-01 US claimed
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-09 US claimed
EP-1403235-A1 N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Dainippon Pharmaceutical Co., Ltd. (JP) 2004-03-31 EP claimed
US-7084176-B2 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2006-08-01 US disclosed
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same DAINIPPON PHARMACEUTICAL CO., LTD. (JP) 2004-12-09 US disclosed
EP-1403235-A1 N-ARYLPHENYLACETAMIDE DERIVATIVES AND MEDICINAL COMPOSITIONS CONTAINING THE SAME Dainippon Pharmaceutical Co., Ltd. (JP) 2004-03-31 EP disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040248983-A1 N-arylphenylacetamide derivatives and medicinal compositions containing the same HRH2, CCR8, CYP2C8 KMT2A 1631/4885SMN1; SMN2 2474/4885LMNA 3086/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.